Arthrosamid®, an intra-articular polyacrylamide hydrogel injection (iPAAG), is a new type of treatment for knee osteoarthritis that offers patients an effective alternative to the currently available therapies. Based on an innovative non-biodegradable hydrogel technology, Arthrosamid® is 97.5% water with 2.5% being a cross-linked polyacrylamide backbone. When injected into the knee, Arthrosamid® cushions the joint in a different way in comparison to standard injections and reduces pain. It works on the synovium and reduces inflammation, providing safe and sustained relief, all with one injection.
Once the iPAAG is injected into the inner joint cavity, it restores viscosity within the synovial fluid, improving lubrication and cushioning of the joint. Arthrosamid® also integrates into the synovium of the inner joint capsule creating a cushion-like effect.. Book Online
Arthrosamid® is different from Viscosupplement injections for the knee such as hyaluronic acid (HA), platelet-rich plasma (PRP) and regenerative stem cell therapy. Unlike these treatments, Arthosamid® is a non-degradable hydrogel which means it has the properties to lubricate and cushion for longer.
Unlike the other treatments, Arthosamid® also has the ability to become an integrated part of the soft synovial tissue in the joint capsule which may lead to longer-lasting pain relief.
In a number of clinical trials with Arthrosamid®, there were no serious side effects related to the hydrogel. The most commonly reported side effects were mild to moderate injection site pain and swelling, which were generally transient in nature. The overall safety profile of hydrogel has been established over the last 20 years with its use for various indications in the body.